Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Lotiglipron in T2DM and Obesity
NCT05158244Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing Lotiglipron with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (All Causalities), Number of Participants With Treatment-emergent Adverse Events (Treatment Related) and 3 more. Started Dec 2021; status: completed.
02
Drugs
lotiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05158244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158244.